ALLSCHWIL/BASEL, Switzerland, May 4, 2007 (PRIME NEWSWIRE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved all resolutions.
Shareholders approved the annual report, including the financial statements, for the year 2006 and confirmed Ernst & Young to serve as the company's auditor for the year 2007.
Shareholders also approved the resolutions affecting the company's capital structure:
* Increase of the Conditional Capital by CHF 4'160'037
(1'664'015 million shares prior to the share split),
reserved for the issuance of employee stock options (ESOP)
* Increase of Conditional Capital by CHF 9.25 million (3.7
million shares prior to the share split), reserved for the
issuance of convertible bonds
* Creation of Authorized Capital of CHF 17.5 million
(7 million shares prior to the share split), to expire
4 May 2009
* Splitting Actelion shares by five, resulting in a new nominal
value per bearer share of CHF 0.50 (previously CHF 2.50)
The shareholders also re-elected Werner Henrich, Jean Malo and Armin Kessler to serve for an additional three years on the Actelion Board of Directors. The composition of the board, therefore, remains unchanged. The eight members are: Robert E. Cawthorn (Chairman), Andre J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin Kessler, Jean Malo, Juhani Anttila and Carl Feldbaum.
The Annual General Meeting of Actelion took place in Basel. It was attended by 180 shareholders, representing 7'614'285 shares or 32 percent of the total outstanding shares.
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(r), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(r) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan as well as Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).
For further information please contact:
Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil
Investor Contact Roland Haefeli +41 61 565 64 58
+1 650 624 6936
Media Contact Peter Engel +41 61 565 66 28
+1 650 624 6996
http://www.actelion.com